

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problems Mailbox.**



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : G01N 33/48	A1	(11) International Publication Number: WO 91/19978 (43) International Publication Date: 26 December 1991 (26.12.91)
(21) International Application Number: PCT/US91/04267 (22) International Filing Date: 14 June 1991 (14.06.91) (30) Priority data: 539,999 15 June 1990 (15.06.90) US (71) Applicants: ST. MARY'S HOSPITAL AND MEDICAL CENTER, INC. [US/US]; 7th and Patterson, Grand Junction, CO 81501 (US). UNITED STATES DEPARTMENT OF ENERGY [US/US]; Washington, DC 2000 (US). (72) Inventors: COLE, Dean, A. ; 60 San Juan Street, Los Alamos, NM 87544 (US). MOODY, David, C., III ; 402 Pine Tree Lane, Boulder, CO 80304 (US). ELLINWOOD, L., Edward ; 694 Sperber Lane, Grand Junction, CO 81506 (US). KLEIN, M., Gerard ; 715 Victor Drive, Grand Junction; CO 81506 (US).		(74) Agents: TOMPKINS, Michael, L. et al.; Sheridan, Ross & McIntosh, One United Bank Center, 1700 Lincoln Street, 35th Floor, Denver, CO 80203 (US). (81) Designated States: AT, AT (European patent), AU, BB, BE (European patent), BF (OAPI patent), BG, BJ (OAPI patent), BR, CA, CF (OAPI patent), CG (OAPI patent), CH, CH (European patent), CI (OAPI patent), CM (OAPI patent), DE, DE (European patent), DK, DK (European patent), ES, ES (European patent), FI, FR (European patent), GA (OAPI patent), GB, GB (European patent), GN (OAPI patent), GR (European patent), HU, IT (European patent), JP, KP, KR, LK, LU, LU (European patent), MC, MG, ML (OAPI patent), MN, MR (OAPI patent), MW, NL, NL (European patent), NO, PL, RO, SD, SE, SE (European patent), SN (OAPI patent), SU, TD (OAPI patent), TG (OAPI patent). Published <i>With international search report.</i>
(54) Title: USING 5,10,15,20-TETRAKIS(4-CARBOXYPHENYL)PORPHINE FOR DETECTING AND TREATING LUNG CANCERS (57) Abstract Method using tetra-aryl porphyrins for and, in particular, 5,10,15,20-tetrakis(4-carboxyphenyl)porphine as a fluorescent tracer for cancers of the lung, and as a radiotracer therefor as a complex with ⁶⁷ Cu. The latter complex also provides a source of beta radiation for selective destruction of lung malignancies as well as gamma radiation useful for image analysis of the situs thereof by single photon emission computed tomography, as an example, both <i>in vivo</i> . Copper-64 may be substituted for the ⁶⁷ Cu if only radiotracer characteristics are of interest. This lighter isotope of copper is a positron emitter, and positron emission tomography techniques can be used to locate the malignant tissue mass.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

Using 5, 10, 15, 20-Tetrakis (4-Carboxyphenyl) Porphine for
Detecting and Treating Lung Cancers

Background of the Invention

The present invention relates generally to the use of
5 porphyrins to detect lung cancer, and more particularly to
the use of tetra-aryl porphyrins, of which 5,10,15,20-
tetrakis(4-carboxyphenyl)porphine is an example, to detect
and treat lung cancer. This invention is the result of
Contract No. W-7405-ENG-36 between the Regents of the
10 University of California and the U.S. Department of Energy.

Cancer of the lung is a major world health problem and
remains untreatable. It has been determined that in 1986
malignant lesions of the lung killed more than three times
as many men as cancer of the colon and surpassed breast
15 cancer as the major lethal malignant disease in women.
Despite an enormous commitment of resources during the past
decade, the success in the management of lung cancer has
been minimal at best. In fact, in 1988, the annual death
rate for lung cancer in the United States was estimated to
20 approach 110,000 deaths. In addition, 150,000 new cases of
lung cancer were diagnosed in 1988, making lung cancer the
number one cancer killer. Attempts at mass-screening high
risk populations have also been unsuccessful.

The treatment of lung cancer has largely been
25 unsuccessful and at times controversial. The overall five-
year survival for a patient with lung cancer still remains
less than 10%. The practice of surgically resecting the
tumor is the most successful of all treatments; however, in

most cases the malignant lesions recur or metastasize. The use of radiotherapy and chemotherapy have also had limited success in prolonging the life of lung cancer patients. In fact, the median survival for a patient with small cell
5 lung carcinoma, who is treated with chemotherapy and with or without radiation therapy is 10-15 months in patients with "limited" disease, and 7-11 months in patients with "extensive" disease.

The association between lung cancer and cigarette
10 smoke is well established; however, other environmental factors also play a role in the etiology of lung cancer. One of these environmental agents is radon-222, a noble gas that is ubiquitous in the natural environment, is created by the decay of radium, which is in turn derived from the
15 decay of uranium. Uranium is present in the earth's crust throughout the world. Radon gas forms in the earth's surface during uranium decay and diffuses into the atmosphere, where it becomes a health hazard. When radon decays in the atmosphere, its short-lived radioactive
20 daughters (isotopes of polonium, bismuth, and lead) attach themselves to dust particles in the air. These radioactive particles as well as unattached radon daughters are then inhaled into the lungs. Radon and radon daughters give off alpha, beta, and gamma radiation. It is estimated that
25 radon daughters deliver over 95% of the alpha radiation dose to the basal cells in the tracheobronchial epithelium of the lung.

Epidemiologic evidence has determined that exposure to radon and its daughters results in an increased risk of bronchial carcinoma. In the early 60's, cytological techniques were developed to detect lung cancer in uranium miners, who, through multiple processes, are exposed to significant radon and radon daughter inhalation applied to the bronchial epithelium over a period of many years. It has been demonstrated further that the incidence of lung cancer in miners who smoke cigarettes is ten times greater than miners who did not smoke. These pulmonary cytopathology techniques have proven to be a very sensitive procedure for detecting abnormal/cancerous cells in high risk populations, such as uranium miners; however, once neoplastic cells have been identified, the task of localizing the occult carcinoma in the lung can be difficult, and in many cases an impossible problem. Because most in situ lesions cannot be seen with the unaided eye, such lesions must be localized by selective bronchial brushing and blind spur biopsies. These diagnostic procedures require general anesthesia and at least 2-3 hours to perform. The location of such early neoplastic lesions is of significant importance for the treatment of lung cancer. It is believed by many that for the treatment of lung cancer to be successful, the treatment procedure must be started at an early stage of cancer development (in situ). To successfully detect these early malignant lung lesions, new compounds must be developed which can be used

in routine clinical procedures to detect small lung lesions.

Porphyrins and, in particular, hematoporphyrin derivative have been known for many years to have a
5 significant affinity for malignant cancer cells, and have been demonstrated to be useful as diagnostic markers. Tumor cells that have taken up hematoporphyrin fluoresce when illuminated with uv light. However, the specificity of uptake of the porphyrins used in the past has not been
10 as complete as desirable; that is, there is a substantial background of fluorescence from noncancerous cells accompanying the fluorescence from the cells of interest. Hematoporphyrin derivative has been used more recently for the imaging of neoplastic invasion of the bladder in
15 humans. The procedure involves endoscopic exploration of the suspected tumor site with instrumentation that will detect fluorescent emission arising from the excitation of porphyrins with 400 nm light.

Porphyrins have also been used in the diagnosis and
20 localization of small radiologically occult lung tumors (D. A. Cortese et al., "Hematoporphyrin Derivative In The Detection And Localization of Radiographically Occult Lung Cancer," Am. Rev. Respir. Dis. 126, 1087 (1982); H. Kato et al., "Early Detection of Lung Cancer By Means of
25 Hematoporphyrin Derivative Fluorescence And Laser Photoradiation," Clin. Chest Med. 6, 237 (1985). In these studies, a photoelectric fluorescence detection system in combination with a conventional bronchoscope was used to

identify and localize early squamous cell carcinomas in patients with normal chest radiographs. K. B. Patel et al., "Fluorescing Cells In Sputum After Parenteral HPD," in Progress In Clinical And Biological Research, Vol. 170, D. Doiron and C. Gomer, Eds.; "Porphyrin Localization And Treatment Of Tumors," pp. 521-530 (1984) have also demonstrated that malignant cells could be detected in sputum samples from lung cancer patients injected with hematoporphyrin derivative. In this study, malignant cells as well as some nonmalignant cells fluoresced up to 9 days following the intravenous injection of the porphyrin. The uptake of porphyrin in normal cells is not unusual because other tissues, such as embryonic and traumatized tissues have also been reported to localize hematoporphyrin derivative.

The localization of malignant lesions using the procedures described above is dependent upon the visual detection of the red fluorescent emission of the porphyrin. In most procedures, this is accomplished by scanning the lung with a bronchoscope adapted to emit light at a wavelength (400 nm) which will excite the porphyrin molecules. The limiting factor with this procedure is that it is time consuming and requires highly trained personnel to examine all areas of the lung for malignant lesions. Because the fluorescent emission from these small lesions is so weak and difficult to observe, small lesions can easily be missed. In addition, to visually detect porphyrin fluorescence, the porphyrin must be on the

surface of the tumor and the tumor must lie on the surface of the lung. Any material, such as mucous covering, or the situation where a tumor is deep-seated, interferes with the overlying detection of porphyrin fluorescence. As a
5 result, porphyrins have not been used successfully as a diagnostic tool for occult lung lesions.

Accordingly, it is an object of the present invention to provide a method for locating small occult malignant tumor masses in the lungs of patients.

10 Another object of our invention is to provide a method for selective irradiation of occult malignant tumor masses in the lungs of patients.

Yet another object of the present invention is to provide a rapid, high-contrast procedure for detecting the
15 presence of malignant cells in vitro.

Additional objects, advantages, and novel features of the invention will be set forth in part in the description which follows, and in part will become apparent to those skilled in the art upon examination of the following or may
20 be learned by practice of the invention. The objects and advantages of the invention may be realized and attained by means of the instrumentalities and combinations particularly pointed out in the appended claims.

Summary of the Invention

25 To achieve the foregoing and other objects, and in accordance with the purposes of the present invention, as

embodied and broadly described herein, the method hereof for detecting lung cancer in vitro includes producing a single cell suspension of lung cells, treating the single cell suspension of lung cells with a tetra-aryl porphyrin and, in particular, 5,10,15,20-tetrakis(4-carboxyphenyl)porphine for sufficient time to ensure significant uptake thereof by neoplastic lung cells present in the single cell suspension of lung cells, exposing the treated cell suspension with ultraviolet radiation in order to induce fluorescence in 5,10,15,20-tetrakis(4-carboxyphenyl)porphine taken up by the neoplastic cells, and evaluating the suspension for fluorescing cells.

Preferably, the single cell suspension is fixed with either carbowax and alcohol, or with paraformaldehyde.

In another aspect of the present invention, in accordance with its objects and purposes, the method for treating lung cancer, hereof includes introducing a sample of the ^{67}Cu complex of tetra-aryl porphyrin and, in particular, 5,10,15,20-tetrakis(4-carboxyphenyl)porphinato into the patient to be treated. Note that according to usual chemical terminology free-base porphyrins are termed "porphines," while complexed porphyrins bear the "porphinato" label.

In yet another aspect of our invention, in accordance with its objects and purposes, the method for locating sites of lung malignancies in vivo hereof includes introducing a sample of the ^{67}Cu or the ^{64}Cu complex of a tetra-aryl porphyrin and, in particular, 5,10,15,20-

tetrakis(4-carboxyphenyl)porphinato into the patient to be treated, and performing image analysis of the emitted gamma radiation or positron emission tomography on the emitted positrons, respectively.

5 Benefits and advantages of the present invention include efficient, expeditious and economical identification of lung cancer cells in sputum samples and in biopsies, by bronchoscopic investigation of lungs, and by gamma ray imaging or positron emission tomography, as
10 well as the site-selective ionizing radiation treatment of lung cancer masses without having to apply surgical techniques.

Brief Description of the Drawings

The accompanying FIGURE, which is incorporated in and
15 forms a part of the specification, illustrates an embodiment of the present invention and, together with the description, serves to explain the principles of the invention.

The FIGURE represents the structural formula for
20 5,10,15,20-tetrakis(4-carboxyphenyl)porphine (A), and that for the complex of this porphyrin and ^{67}Cu (B).

Detailed Description of the Preferred Embodiments of the Invention

Briefly, the present invention includes the use of
25 tetra-aryl porphyrins and, in particular, 5,10,15,20-

tetrakis(4-carboxyphenyl)porphine (TCPP) as a fluorescent tracer for lung cancer cells, and as a radiotracer therefor as a complex with ^{67}Cu . The latter complex also provides a source of beta radiation for selective destruction of lung malignancies as well as gamma radiation useful for image analysis of the situs thereof by single photon emission computed tomography, for example. ^{64}Cu may be substituted for the ^{67}Cu if only radiotracer characteristics are of interest. The copper-64 isotope of copper is a positron emitter, and well-known positron emission tomography techniques can be used to locate the malignant tissue mass. These uses derive from the affinity TCPP and those from the same family of porphyrins have for lung malignancies when introduced into the vicinity of such cells.

Reference will now be made in detail to the present preferred embodiments of the invention, an example of which is illustrated in the accompanying Figure.

The FIGURE represents the structural formula for one example of a class of tetra-aryl porphyrins which may be used to practice the present invention, 5,10,15,20-tetrakis(4-carboxyphenyl)porphine, TCPP, (A), and that for the complex of this porphyrin and ^{67}Cu (B). A first investigation was conducted to determine whether TCPP would localize in neoplastic sputum cells obtained from uranium miners, and under what conditions would this process be maximized. A second study examined the localization of TCPP in different types of lung cancer cells (squamous cell, small cell, metastatic lung lymphoma, and

adenocarcinoma), and the ability to diagnose lung cancer in such patients using TCPP.

A. Localization Of TCPP In Neoplastic Sputum Cells:

Five parameters were investigated for this study: (1) the effect of various sputum processing procedures on the uptake of porphyrin in sputum cells, (2) the comparison of TCPP to three other porphyrins that are known for their uptake by tumors, (3) the time required for optimal uptake of the porphyrin in sputum cells, (4) the uptake of porphyrin in test and control sputum samples, and (5) the verification that TCPP was localizing in malignant sputum cells. In each of these investigations, the uptake of porphyrin in sputum cells was evaluated with a fluorescent microscope. Nonmetallated porphyrin fluoresces at approximately 650 nm. Sputum samples were evaluated for (1) the number of cells in the sputum samples which fluoresced, and (2) the intensity of the porphyrin fluorescence.

1. Processing Procedures:

Sputum samples require processing in order to produce a single cell suspension of lung cells. Sputum samples from test and control patients were collected and processed with alcohol and carbowax, alcohol only, phosphate buffered saline (PBS), or left unprocessed. All samples were mixed with a blender for 1 minute following the addition of the

11

processing mixture and then placed into petri dishes containing various porphyrins. Sputum samples processed with alcohol and carbowax or alcohol (no carbowax) had a larger number of cells free of the mucous than samples processed with PBS or unprocessed samples. Cells in the unprocessed sputum samples remained attached to the bottom of the petri dish with only a few cells free of the mucous. Sputum samples processed with PBS had the greatest number of live cells when compared to sputum samples processed with alcohol or alcohol/carbowax; however, sputum cells processed with alcohol or alcohol/carbowax had the highest TCPD uptake, suggesting that TCPD may have an affinity for nonviable processed cells.

2. Evaluation Of Different Porphyrins:

Four porphyrins selected for their known affinity for neoplastic cells were tested for their ability to detect malignant sputum cells. Sputum cells obtained from each of the four processing procedures set forth above were treated with one of hematoporphyrin derivative, HPD, 5,10,15,20-tetrakis(4-carboxyphenyl)porphine, TCPD, 5,10,15,20-tetrakis(4-sulfonatophenyl)porphine, TTPS, or uroporphyrin, URO. In all investigations, the porphyrins were dissolved in tissue culture medium at a concentration of 200 µg/ml. Following the addition of porphyrin, each sample was incubated at 37°C for a specific length of time.

SUBSTITUTE SHEET

Following the incubation period, each sputum sample was examined for porphyrin uptake with a fluorescent microscope. The background fluorescence from porphyrin uptake by nonmalignant cells was lower in some measurements. Sputum samples which had been incubated with TCPP had the greatest number of cells fluorescing and the greatest contrast (brightness) between fluorescing malignant cells and background fluorescence, indicating significant porphyrin uptake in the malignant bodies. Sputum samples processed with HPD and TPPS had moderate porphyrin uptake, and samples processed with URO had the least porphyrin uptake.

3. Incubation Time:

Each sputum sample was incubated at 37°C with each of the porphyrins for either 6 or 24 hours and then evaluated for porphyrin uptake with a fluorescent microscope. At the 6 hour incubation period, the cells had begun to localize porphyrin; however, when the sputum cells were washed with PBS, the fluorescence diminished considerably. This suggests that the porphyrin was not firmly bonded to the cells. By 24 hours, by contrast, the uptake of porphyrin by sputum cells increased considerably. This was demonstrated by the number of cells which had taken up porphyrin and the intensity of porphyrin fluorescence. When the sputum cells that had been incubated for 24 hours

were washed with PBS, the porphyrin remained attached to the cells. Longer incubation times were not investigated.

4. Uptake In Test And Control Samples:

Control sputum samples did not contain neoplastic
5 cells. However, a large number of inflammatory cells were found to be present. When porphyrin uptake in the test and control samples were compared (i.e., the number of sputum cells which fluoresced), the porphyrin uptake in the control samples was considerably lower than the uptake in
10 the test samples. In addition, the fluorescence intensity of the few control cells that did fluoresce was lower than the fluorescence intensity of the test cells. The most dramatic difference between the uptake of porphyrin by test and control sputum cells was seen in samples incubated with
15 TCPP.

5. Identification Of Sputum Cells Which Fluoresced:

To assist in the identification of the neoplastic cells, sputum samples which had the greatest TCPP uptake were stained with PAP stain, a stain routinely used by
20 cytologists to identify neoplastic cells. Cells identified as neoplastic using the PAP stain were marked and re-examined for TCPP uptake with a fluorescent microscope. Although the fluorescence intensity of the TCPP had been reduced by the PAP staining procedure, TCPP fluorescence
25 was seen in every neoplastic cell.

B. Localization Of TCPP In Different Types of Lung Cancers:

Studies were conducted using patients having confirmed squamous cell lung carcinoma, oat cell lung carcinoma, lung
5 adenocarcinoma, and advanced metastatic lymphoma (lung metastasis) using procedures identical to those set forth above. Using as a measure the number of fluorescent cells in a sputum sample times the fluorescence intensity of the cells, it was found that this number was 3-6 times greater
10 for sputum samples from cancer patients than for noncancerous patients. These studies also confirm that TCPP and carbowax and ethanol resulted in the greatest uptake of porphyrin in neoplastic sputum cells.

Further investigations determined that TCPP also
15 localizes in cancers of the lung grown in tissue cultures. Moreover, squamous carcinoma cells grown in culture and treated with TCPP can easily be detected using flow cytometry, and that autofluorescence of control cells (cells not exposed to TCPP) was negligible when compared to
20 the fluorescence of cells exposed to TCPP. Expanding the investigations to other types of lung cells, it was found that human small cell (oat cell) lung carcinoma absorbed TCPP in 2-3 times lower quantities than did the squamous cell line, but this is still considerably higher than
25 uptake in normal cells. It was also found that normal human lung epithelial cells concentrated TCPP at only slightly above autofluorescence or background levels; that

is, at many times lower concentration than that TCPF concentration in the neoplastic cell lines examined. Incubating the cells for 24 hours in TCPF was more than adequate to maximize the TCPF localization, and fixing the cells prior to TCPF exposure increased the TCPF uptake. Paraformaldehyde as a fixant was found to slightly increase the TCPF uptake of the cells over those fixed with alcohol and carbowax.

C. Supportive Investigations Using ^{67}Cu :

10 1. Production of Copper-67 and Copper-67/Porphyrin Complex:

The production of copper-67 involves the irradiation of a zinc oxide target with 600 to 800 MeV protons for several days. The spallation reaction in the target produces not only ^{67}Cu , but also a several other isotopes of lighter mass than zinc. The purification procedure is complicated and involves the separation of ^{67}Cu from zinc and other metals by electrochemical plating (J. A. Mercer-Smith et al., "The Development Of Copper-67 Labeled Porphyrin-Antibody Conjugates," in Targeted Diagnosis And Therapy, Vol. 1, Antibody-Mediated Delivery Systems; J. T. Rodwell, Ed. (Marcel Dekker, New York, 1988) pp. 317-352). Preparation of $^{67}\text{CuTCPF}$ is achieved from either N-bzHTCPF or TCPF by radiometallation with $^{67}\text{CuCl}_2$.

25 2. Serum Stability of ^{67}Cu TCPF:

An important consideration in the development of a radiopharmaceutical is the stability of the complex ^{67}Cu

TCPP to the loss of the radioisotope ^{67}Cu in vivo. To test the stability of $^{67}\text{CuTCPP}$, a fluorescence method capitalizing on the fact that copper porphyrins do not fluoresce, while nonmetallated do, was developed by which
5 the loss of copper could be measured under simulated physiological conditions (J. C. Roberts et al., "Preparation and Characterization of Copper-67 Porphyrin-Antibody Conjugates," J. Immunol. Methods 105, 153 (1987). It was found that the stability of CuTCPP in human serum
10 albumin, and two chelating agents, EDTA and DTPA was such that less than one percent conversion (the limit of detection) occurred in incubation periods of up to 12 days. In addition, there was no detectable transcomplexation with other metal ions as indicated by ultraviolet-visible
15 spectroscopy.

3. Biodistribution And Biological Half-Life Of $^{67}\text{CuTCPP}$:

A sterile dose of $^{67}\text{CuTCPP}$ (1.0×10^{-6} gm) was intravenously injected into the tail vein of rats. It was
20 determined that the liver and kidney of these normal animals (no cancer) were the major organs of $^{67}\text{CuTCPP}$ localization. From these results, it can be concluded that $^{67}\text{CuTCPP}$ is suitable for detection and treatment of cancerous lung tissue in vivo, since normal lung tissue
25 does not appear to take up significant quantities of $^{67}\text{CuTCPP}$, making lung tumor to normal lung cell uptake ratios substantial. A biological half-life study demonstrated that $^{67}\text{CuTCPP}$ is biologically eliminated from

SUBSTITUTE SHEET

the animals following a normal exponential decay curve, with a half-life of 108 hours.

The foregoing description of several preferred embodiments of the invention have been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the invention to the precise form disclosed, and obviously many modifications and variations are possible in light of the above teaching. For example, it would be apparent to one having ordinary skill in the art of cancer detection and treatment after studying the present disclosure that a method for locating the situs of lung malignancies in vivo, could include injecting a sample of the ^{64}Cu complex of 5,10,15,20-tetrakis(4-carboxyphenyl)prophinato into the bloodstream, or directing an aerosol containing this complex into the lungs of a patient to be diagnosed, and performing positron emission tomography (G. Firnaeu et al., " ^{64}Cu Labelling of Hematoporphyrin Derivative For Non-Invasive In-Vivo Measurements Of Tumour Uptake," in Progress In Clinical And Biological Research, Vol. 170, D. Doiron and C. Gomer, eds.; "Porphyrin Localization And Treatment Of Tumors," pp. 629-636 (1984)). For radioisotope labeling using isotopes having long-half-lives, it would be apparent to an individual having such skill in the relevant art that it would also be effective to introduce the ^{64}Cu complexes into tissue for subsequent diffusion into the bloodstream. It would further be apparent to a practitioner having ordinary skill that samples could be prepared from biopsies of

SUBSTITUTE SHEET,

tissue masses as well as from sputum samples for in vitro diagnoses.

The embodiments were chosen and described in order to best explain the principles of the invention and its
5 practical application to thereby enable others skilled in the art to best utilize the invention in various embodiments and with various modifications as are suited to the particular use contemplated. It is intended that the scope of the invention be defined by the claims appended
10 hereto.

What is claimed is:

1. A method for detecting cancers of the lung, comprising the steps of producing a single cell suspension of lung cells, treating the single cell suspension of lung cells with 5,10,15,20-tetrakis(4-carboxyphenyl)porphine for
5 sufficient time to ensure significant uptake thereof by neoplastic lung cells present in the single cell suspension of lung cells, exposing the treated cell suspension with ultraviolet radiation in order to induce fluorescence in 5,10,15,20-tetrakis(4-carboxyphenyl)porphine taken up by
10 the neoplastic cells, and evaluating the suspension for fluorescing cells.

2. The method as described in Claim 1, wherein said step of treating the single cell suspension with 5,10,15,20-tetrakis(4-carboxyphenyl)porphine includes incubation of the suspension at elevated temperatures.

3. The method as described in Claim 2, wherein step of treating the single cell suspension further includes fixing the cell sample with carbowax and alcohol.

4. The method as described in Claim 2, wherein said step of treating the single cell suspension further includes fixing the cell sample with paraformaldehyde.

5. The method as described in Claim 1, wherein said step of evaluating the cell suspension for fluorescing cells includes the use of fluorescence imaging techniques, and the suppression of background fluorescence emission.

6. The method as described in Claim 1, wherein said step of treating the single cell suspension further includes thoroughly blending the single cell suspension with 5,10,15,20-tetrakis(4-carboxyphenyl)porphine.

7. The method as described in Claim 1, wherein said step of evaluating the cell suspension for fluorescing cells includes the use of flow cytometry techniques.

8. A method for treating lung cancer, comprising the step of injecting a sample of the ^{67}Cu complex of 5,10,15,20-tetrakis(4-carboxyphenyl)porphinato into the bloodstream of a patient to be treated.

9. A method for locating sites of lung malignancies in vivo, comprising the steps of injecting a sample of the ^{67}Cu complex of 5,10,15,20-tetrakis(4-carboxyphenyl)porphinato into the bloodstream of a patient
5 to be treated, and performing image analysis of the emitted gamma radiation.

10. A method for treating lung cancer, comprising the step of directing an aerosol containing the ^{67}Cu complex of 5,10,15,20-tetrakis(4-carboxyphenyl)porphinato into the lungs of a patient to be treated.

11. A method for locating sites of lung malignancies in vivo, comprising the steps of directing an aerosol containing the ^{67}Cu complex of 5,10,15,20-tetrakis(4-carboxyphenyl)porphinato into the lungs of a patient to be
5 treated, and performing image analysis of the emitted gamma radiation.

12. A method for locating sites of lung malignancies in vivo, comprising the steps of injecting a sample of the ^{64}Cu complex of 5,10,15,20-tetrakis(4-carboxyphenyl)porphinato into the bloodstream of a patient to be treated, and performing positron emission tomography of the emitted positron radiation.

13. A method for locating sites of lung malignancies
in vivo, comprising the steps of directing an aerosol
containing the ^{64}Cu complex of 5,10,15,20-tetrakis(4-
carboxyphenyl)porphinato into the lungs of a patient to be
5 treated, and performing positron emission tomography of the
emitted gamma radiation.

14. A method for detecting cancers of the lung, comprising the steps of producing a single cell suspension of lung cells, treating the single cell suspension of lung cells with a tetra-aryl porphyrin for sufficient time to ensure significant uptake thereof by neoplastic lung cells present in the single cell suspension of lung cells, exposing the treated cell suspension with ultraviolet radiation in order to induce fluorescence in 5,10,15,20-tetrakis(4-carboxyphenyl)porphine taken up by the neoplastic cells, and evaluating the suspension for fluorescing cells.

15. The method as described in Claim 14, wherein said step of treating the single cell suspension with a tetra-aryl porphyrin includes incubation of the suspension at elevated temperatures.

16. The method as described in Claim 15, wherein said step of treating the single cell suspension further includes fixing the cell sample with carbowax and alcohol.

17. The method as described in Claim 15, wherein said step of treating the single cell suspension further includes fixing the cell sample with paraformaldehyde.

18. The method as described in Claim 14, wherein said step of evaluating the cell suspension for fluorescing cells includes the use of fluorescence imaging techniques, and the suppression of background fluorescence emission.

19. The method as described in Claim 14, wherein said step of treating the single cell suspension further

includes thoroughly blending the single cell suspension with 5,10,15,20-tetrakis(4-carboxyphenyl)porphine.

20. The method as described in Claim 14, wherein said step of evaluating the cell suspension for fluorescing cells includes the use of flow cytometry techniques.

21. A method for treating lung cancer, comprising the step of injecting a sample of the ^{67}Cu complex of a tetra-aryl porphyrin into the bloodstream of a patient to be treated.

22. A method for locating sites of lung malignancies
in vivo, comprising the steps of injecting a sample of the
⁶⁷Cu complex of a tetra-aryl porphyrin into the bloodstream
of a patient to be treated, and performing image analysis
5 of the emitted gamma radiation.

23. A method for treating lung cancer, comprising the step of directing an aerosol containing the ^{67}Cu complex of a tetra-aryl porphyrin into the lungs of a patient to be treated.


24. A method for locating sites of lung malignancies in vivo, comprising the steps of directing an aerosol containing the ^{67}Cu complex of a tetra-aryl porphyrin into the lungs of a patient to be treated, and performing image analysis of the emitted gamma radiation.
- 5

25. A method for locating sites of lung malignancies in vivo, comprising the steps of injecting a sample of the ^{64}Cu complex of a tetra-aryl porphyrin into the bloodstream of a patient to be treated, and performing positron
5 emission tomography of the emitted positron radiation.

26. A method for locating sites of lung malignancies
in vivo, comprising the steps of directing an aerosol
containing the ^{64}Cu complex of a tetra-aryl porphyrin into
the lungs of a patient to be treated, and performing
5 positron emission tomography of the emitted gamma
radiation.

1/1

Figure 1



INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US91/04267

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) *

According to International Patent Classification (IPC) or to both National Classification and IPC

IPC(5): G01N 33/48

U.S.Cl.: 436/64

II. FIELDS SEARCHED

Minimum Documentation Searched ⁷

Classification System

Classification Symbols

U.S.

436/64, 800, 805, 519; 514/410, 185; 435/119, 968

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched *

APS, STN-File Biosis, CA, Medline, Dialog

III. DOCUMENTS CONSIDERED TO BE RELEVANT *

Category *	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	Biosis Abstract, Volume 51, No. 4, issued 1990, SHULOK et al., "Subcellular Localization of Hematoporphyrin Derivative in Bladder Tumor cells in Culture", see page 451-458, abstract no. 90:334016, see entire abstract.	1,2,5,6,7, 14,15,18, 19,20
Y	Biosis Abstract, Volume 42, No. 6, issued 1982, BERNS et al., "In Vitro Cellular Effects of Hematoporphyrin Derivative", pages 2325-2329, see abstract no. 83:277948.	1,2,5,6,7, 14,15,18, 19,20

* Special categorization of cited documents: ¹⁴

"A" document defining the general state of the art which is not
considered to be of particular relevance

"E" earlier document but published on or after the international
filing date

"L" document which may throw doubts on priority claim(s) or
which is cited to establish the publication date of another
citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or
other means

"P" document published prior to the international filing date but
later than the priority date claimed

"T" later document published after the international filing date
or priority date and not in conflict with the application but
cited to understand the principle or theory underlying the
invention

"X" document of particular relevance; the claimed invention
cannot be considered novel or cannot be considered to
involve an inventive step

"Y" document of particular relevance; the claimed invention
cannot be considered to involve an inventive step when the
document is combined with one or more other such docu-
ments, such combination being obvious to a person skilled
in the art.

"A" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

06 September 1991

Date of Mailing of this International Search Report

27 SEP 1991

International Searching Authority

ISA/US

Signature of Authorizing Officer

Thomas E. Daley

Attachment to form PCT/ISA/210
Continuation in part III.
Documents Considered to be
Relevant

- | | | |
|-----|--|----------------------------------|
| Y | Biosis Abstract, Volume 28, No. 3,
issued 1980, MUSSER et al., "The Binding
of Tumor Localizing Porphyrins to a
Fibrin Matrix and Their Effects
following Photo Irradiation", pages 505-
526, see abstract no. 80:266560. | 1,2,5,6,7,
14,15,18,
19,20 |
| Y | US,A, 4,857,300 (MAKSEM) 15 August
1989, see entire document. | 3,4,16,17 |
| Y,P | US,A, 4,930,516 (AIFANO et al.) 05
June 1990. See entire document. | 1,2,5,6,7,
14,15,18,
19,20 |
| Z | US,A, 4,783,529 (Lavallee et al) 08 November
1988 | |